« Selective JAK1 Inhibition Using Upadacitinib for the Management of Inflammatory Bowel Diseases: The Powerful Pill » (2023) Canadian IBD Today, 1(S11), p. 2–11. doi:10.58931/cibdt.2023.1S1121.